Fresh Tracks Therapeutics, Inc., formerly Brickell Biotech, Inc., is a clinical-stage pharmaceutical company engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new molecular entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Kinase Inhibitors and FRTX-03. Its lead program, FRTX-02, is a clinical-stage oral DYRK1A inhibitor for patients with autoimmune diseases to be administered in humans. Its FRTX-10 is a preclinical-stage stimulator of interferon genes (STING) inhibitor candidate. Its Kinase Inhibitors include compounds that inhibit prominent targets.
No insider trading activity.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.